INO-1001 Inhibitor CAS No. 3544-24-9

Cat. No.	Name	Size	Price	Add Cart
KI3355	INO-1001	250 mg	$170

Chemical Characteristic

Product Name	INO-1001
Synonyms	3-Aminobenzamide
CAS No.	3544-24-9
Molecular Weight	136.15
Formula	C₇H₈N₂O
Chemical Name	3-Aminobenzamide
Smiles	C(=O)(c1cc(ccc1)N)N
Chemical Structure

Biological activities

INO-1001 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. INO-1001 at non-cytotoxic concentrations effectively inhibits PARP activity and potently enhances the radiation sensitivity in human and rodent fibroblast cell lines in vitro.^[1] INO-1001 also improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide (H2O2) in vitro.^[2] In vitro, INO-1001 blocks the hyperglycemia-induced ROS generation in podocytes and prevents hyperglycemia-induced nuclear factor-ΚB (NF-ΚB) activation of podocytes. In vivo, INO-1001 treatment decreases diabetes-induced podocyte depletion and ameliorates nephropathy of type 2 diabetic Leprdb/db mice.^[3] In an animal model of regional therapy for the treatment of advanced extremity malignant melanoma, INO-1001 treatment prior to IL-I significantly enhances the efficacy of temozolomide.^[4] Moreover, in an experimental dog model of cardioplegic arrest and extracorporal circulation, INO-1001 administration (1 mg/kg) improves cardiac and pulmonary function.^[5]

Protocols

In vivo, INO-1001 is dissolved in 5% dextrose.^[6]

References

[1] Brock WA, et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004, 205(2): 155-160. [2] Radovits T, et al. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol. 2007, 564(1-3): 158-166. [3] Szabò C, et al. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes. 2006, 55(11): 3004-3012. [4] Toshimitsu H, et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol. 2010, 17(8): 2247-2254. [5] Szabò G, et al. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock. 2004, 21(5): 426-432. [6] Cheng CL, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005, 4(9): 1364-1368.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.